Build-to-Order Layer 1 Systems Deliver in Weeks, Backed by Direct-to-Engineer US Support and Expedited Advance Replacement

REDMOND, Wash., Sept. 24, 2026 /PRNewswire/ -- XKL LLC, a leading provider of Layer 1 optical networking systems, today announced a rapid-fulfillment delivery commitment for its MediaLight™ systems, paired with the launch of CoreAssure, an extended service solution engineered to eliminate operational friction and deployment delays. While some legacy telecom vendors quote hardware backlogs of anywhere from 20 to over 60 weeks, XKL delivers build-to-order DWDM systems in weeks, backed by direct access to senior optical engineers.

CoreAssure redefines optical transport support by eliminating offshored triage queues and multi-tier escalation delays. Combined with fast equipment turnaround, XKL provides complete operational velocity from deployment to Day-2 operations.

Core Operational Advantages

- Rapid Hardware Delivery: Bypasses industry-wide supply chain bottlenecks with build-to-order fulfillment timelines measured in weeks, enabling immediate network turn-up.

- Direct-to-Engineer Engagement: Connects customers directly with 100% US-based optical transport specialists, bypassing lower-tier help desks and scripted queues entirely.

- Expedited Advance Replacement: Replaces standard 10-to-15 business day depot repairs with priority-dispatched, pre-configured replacement units with zero license-activation friction.

- Hitless Maintenance & Firmware Integrity: Delivers supported In-Service Software Upgrades (ISSU) and security patches, updating management firmware while keeping client and line-side traffic fully active.

- Deep Optical Diagnostics: Provides root-cause optical telemetry—including power budget, OSNR, eSNR, and Q-factor analysis—to resolve physical-layer degradation before service is impacted.

"Operators are frustrated by waiting months for hardware, only to be routed to call-center scripts when critical assistance is required," said Casey Inman, Director of Sales & Marketing at XKL. "By pairing weeks-long delivery with CoreAssure, we provide true operational predictability—delivering capacity when it is needed and backing it with direct engineering expertise."

Availability

CoreAssure extended service solutions are available immediately across XKL's DarkStar® product line, spanning the MediaLight and SpectraPath™ product families. For product information, visit xkl.com/products/.

About XKL

XKL delivers accessible DWDM solutions built to eliminate deployment friction. Providing pre-configured, factory-tested Layer 1 appliances instead of piecemeal hardware requiring complex on-site integration, XKL enables plug-and-play turn-up in minutes. Trusted globally, XKL's built-to-order, license-free systems ensure reliable performance across core, middle mile, and backhaul networks. Visit www.xkl.com.

Media Contact:

Carl Sketchley

[email protected]

SOURCE XKL, LLC

Share this article

- Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy

- No IOI observed with short-course prophylactic topical steroids

ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles.

"These latest long-term results are highly encouraging and reinforce the potential of sura-vec to change the treatment landscape for the millions of patients with non-proliferative diabetic retinopathy," said Steve Pakola, M.D., Chief Medical Officer of REGENXBIO. "Building on the positive data seen at two and two and a half years after a single treatment, the three-year data continues to show meaningful improvements in DRSS alongside a reduction in disease progression. The durability of these results strengthens our conviction in sura-vec as a potentially transformative, one-time treatment."

"For patients with non-proliferative diabetic retinopathy, the goal is to intervene before the disease progresses to vision-threatening complications and irreversible vision loss. However, current preventive treatment requires repeat injections, which is a significant burden for a population that is largely working-age adults," said Nikolas London, M.D., FACS, FASRS, Retina Consultants San Diego, ALTITUDE study investigator. "These three-year ALTITUDE results are encouraging and support continued study of sura-vec as a one-time, in-office treatment with the potential to change the course of the disease. A single treatment that reduces or eliminates the need for ongoing intraocular injections, and reduces the risk of vision-threatening complications, would be a meaningful change for our diabetic patients."

Phase II ALTITUDE Long-term follow up data (as of August 17, 2026)

In long-term follow-up from the Phase II ALTITUDE® trial, a single in-office administration of sura-vec using suprachoroidal delivery in participants with non-proliferative DR (NPDR) at Dose Level 3 (1.0×10¹² GC/eye) with short-course prophylactic topical steroids demonstrated a durable efficacy profile at three years with no new sura-vec-related safety signals observed during long-term follow up. 60% of all Dose Level 3 participants with three-year visits (n=6/10) achieved >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) without additional treatment for diabetic retinopathy.1 These participants did not experience any vision-threatening events.

Additionally, the majority of participants (n=3/4) who achieved a 1-step DRSS improvement at one year without supplemental anti-VEGF injections went on to achieve a >2-step DRSS improvement by three years without additional treatment for diabetic retinopathy.

There were no new sura-vec-related safety signals and no intraocular inflammation observed through three years (n=17) with short-course prophylactic topical steroids.

These data are consistent with previously presented two and a half-year Dose Level 3 NPDR data from the ALTITUDE trial and support the potential of one-time in-office sura-vec to modify the underlying disease and decrease risk of vision-threatening events. Dose Level 3 is being evaluated in the Phase IIb/III NAAVIGATE trial of sura-vec in NPDR.

About Surabgene Lomparvovec (sura-vec, ABBV-RGX-314)

Sura-vec is a one-time investigational gene therapy designed to deliver sustained treatment effect in wet AMD, diabetic retinopathy and other chronic retinal conditions. Sura-vec uses the NAV® AAV8 vector to encode an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). The sura-vec transgene protein inhibits the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.2

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults between 24 and 75 years of age worldwide.3 DR affects nearly 10 million people in the United States alone.4 The spectrum of DR severity ranges from non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR).4 As DR progresses, a large proportion of patients develop vision-threatening events, including diabetic macular edema (DME) and neovascularization that can lead to blindness.5 Current treatment options for patients with NPDR typically include "watchful waiting" or anti-VEGF treatment. For patients with PDR, current treatment options include anti-VEGF treatment or retinal laser; surgical treatment may be required for advanced PDR.2 

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

FORWARD-LOOKING STATEMENTS

This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations and clinical trials, the timing, availability and interpretation of clinical data. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including risks related to the FDA's review process, the timing of enrollment, commencement, completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of any milestone payments, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zolgensma® and ITVISMA® are registered trademarks of Novartis AG. All other trademarks referenced herein are registered trademarks of REGENXBIO.

Contacts:

Dana Cormack

Corporate Communications

dcormack@regenxbio.com 

Investors:

George E. MacDougall

Investor Relations

IR@regenxbio.com

1 One participant who achieved a ≥2-step DRSS improvement at Year 2 received two supplemental anti-VEGF injections after Year 2 despite no evidence of disease progression or center-involved DME in the study eye; investigator elected to treat the study eye concurrently with treatment of the fellow eye for center-involved DME. Participant was lost to follow-up and had no Year 3 data.

*These are interim results from analyses performed by REGENXBIO for an ongoing trial.

2 Penn JS, Madan A, Caldwell RB, et al.

The article outlines how combining home insurance and auto insurance affects savings, flexibility, and long-term coverage decisions for Texas families.

FLOWER MOUND, Texas, Sept. 24, 2026 /PRNewswire/ -- Is bundling home and auto insurance worth it for Texas families? HelloNation has published an article that provides clear guidance on insurance bundling, including potential savings, trade-offs, and how to evaluate coverage options effectively.

The HelloNation article explains that bundling insurance is often appealing because it can lead to meaningful insurance discounts. Many insurers offer reduced premiums when home insurance and auto insurance are combined under one provider. For Texas families in Flower Mound, these savings can range from 10 to 25 percent, making bundling insurance an attractive way to lower overall costs while simplifying policy management.

The article explains how managing multiple policies through a single provider can make policy management more efficient. Families benefit from a single billing process, fewer accounts to track, and a more streamlined claims experience. This convenience is especially helpful for busy households in Flower Mound, as it helps balance multiple vehicles and property responsibilities. The article notes that combining home insurance and auto insurance can also open the door to additional insurance discounts when other policies are added.

However, the article emphasizes that bundling insurance is not always the best solution for every situation. While insurance discounts can be appealing, the article notes that bundled coverage options may sometimes limit flexibility. For example, a bundled plan might not include specific endorsements or higher liability limits that a family may want for their home insurance or auto insurance policies. This underscores the importance of Texas families carefully reviewing all coverage options before making a decision.

The HelloNation article highlights that comparing bundled policies with separate plans is a critical step. While bundling insurance can reduce costs, the article explains that the lowest price does not always provide the best protection. Evaluating coverage options side by side helps ensure that both home insurance and auto insurance policies meet individual needs. Insurance Agent insights featured in the article stress that coverage quality should remain the top priority.

Another important factor discussed is how personal circumstances influence whether bundling insurance makes sense. The article notes that Texas families with multiple vehicles or higher-value homes in Flower Mound may benefit more from bundling insurance due to increased insurance discounts. On the other hand, families with unique coverage needs may find better solutions by keeping policies separate, thereby maintaining flexibility in their coverage options.

The article also explores customer service considerations. When a single provider handles both home and auto insurance, communication can be more straightforward, and claims may be easier to manage. This can improve the overall experience for Texas families. At the same time, the article points out that relying on a single insurer for all policies carries some risk if service quality declines or circumstances change.

Long-term planning is another key theme in the article. Changes such as adding vehicles, renovating a home, or adjusting liability limits can affect the effectiveness of insurance bundling over time. The article explains that regularly reviewing policies helps ensure coverage options continue to align with evolving needs. Maintaining flexibility in policy management is essential for adapting to these changes.

The article concludes that bundling insurance can be a practical and cost-effective option, but only when it aligns with a family's full coverage needs. Careful comparison of insurance discounts, policy management benefits, and available coverage options allows Texas families in Flower Mound to make informed decisions that balance savings with protection.

Is Bundling Home and Auto Insurance Worth It for Texas Families? features insights from Tammy Edwards, Insurance Agent, Experts of Flower Mound, Texas, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

SOUTHLAKE, Texas, Sept. 24, 2026 /PRNewswire/ -- Sabre Corporation ("Sabre") (Nasdaq: SABR) today announced the results of the previously announced cash tender offers (the "Tender Offers") by Sabre GLBL Inc. ("Sabre GLBL"), its indirect wholly-owned subsidiary, for Sabre GLBL's securities set forth in the table below (collectively, the "Securities"). The Tender Offers expired at 5:00 p.m., New York City time, on September 24, 2026 (such date and time, the "Expiration Date").

The Tender Offers were made pursuant to the terms and conditions set forth in the offers to purchase, dated September 15, 2026 (the "Offer to Purchase").

As of the Expiration Date, according to information provided to D.F. King & Co., Inc., the tender and information agent for the Tender Offers (the "Tender Agent"), the aggregate principal amount of each series of Securities listed in the table below was validly tendered and not validly withdrawn in the Tender Offers. Withdrawal rights for the Securities expired at the Expiration Date and, accordingly, any Securities that were validly tendered may no longer be withdrawn except where additional withdrawal rights are required by law.

The Tender Offers remain subject to the satisfaction or waiver of the conditions described in the Offer to Purchase, including the financing for the Tender Offers. Such conditions may be waived by Sabre GLBL in its sole discretion, subject to applicable law. Any waiver of a condition by Sabre GLBL will not constitute a waiver of any other condition. Subject to the satisfaction or waiver of such conditions and as described in the Offer to Purchase, Sabre GLBL is expected to make payment on September 28, 2026 (such date and time, as it may be extended, the "Settlement Date") for the Securities that (i) were validly tendered and not validly withdrawn at or prior to the Expiration Date and (ii) are accepted for purchase on the Settlement Date.

As the Aggregate Purchase Price of all validly tendered and not validly withdrawn 10.750% Senior Secured Notes due 2029 (the "10.750% 2029 Notes") exceeds $250 million, no validly tendered 10.750% Senior Secured Notes due 2030 or 11.125% Senior Secured Notes due 2030 will be accepted for purchase, and the 10.750% 2029 Notes will be accepted on a pro rata basis and will be subject to a proration factor of approximately 84.0%. Securities tendered and not purchased on the Settlement Date will be returned to holders of Securities (the "Holders") promptly after the Settlement Date. The consideration to be paid for the 10.750% 2029 Notes accepted for purchase on the Settlement Date per $1,000 principal amount of such Securities is the amount set forth in the table above under the heading "Purchase Price." All Holders of 10.750% 2029 Notes accepted for purchase will also receive accrued interest from, and including, the most recent interest payment date preceding the Settlement Date to, but not including, the Settlement Date.

Sabre GLBL expressly reserves the right, in its sole discretion, subject to applicable law, to: (i) terminate any or all of the Tender Offers and not accept for purchase any of the Securities not theretofore accepted for purchase in the terminated Tender Offer or Tender Offers, (ii) waive any and all of the conditions to the Tender Offers on or prior to the time the Securities are accepted for purchase in any or all of the Tender Offers, (iii) extend the Expiration Date to a later date and time, (iv) increase or decrease the maximum Aggregate Purchase Price, or (v) otherwise amend the terms and conditions of the Tender Offers.

The aggregate amount that all Holders are entitled to receive for their Securities that are accepted for purchase by Sabre GLBL in the Tender Offers, excluding accrued interest, is referred to as the "Aggregate Purchase Price." "Aggregate Maximum Tender Amount" refers to the maximum principal amount of Securities that can be purchased for cash in the Tender Offers without resulting in the Aggregate Purchase Price exceeding $250 million.

Information Relating to the Tender Offers

The complete terms and conditions of the Tender Offers are set forth in the Offer to Purchase. BofA Securities is the Dealer Manager for the Tender Offers. Investors with questions regarding the Tender Offers may contact BofA Securities, collect: (980) 388-3646, toll-free: (888) 292-0070, email: [email protected]. D.F. King & Co., Inc. is the tender and information agent for the Tender Offers. Copies of the Offer to Purchase and any related offer documents may be obtained by contacting D.F. King & Co., Inc. by phone at (646) 455-1060 (New York) or (866) 356-7814 (toll-free) or by email at [email protected]. Copies of the Offer to Purchase are available at: www.dfking.com/sabre.

None of Sabre GLBL, Sabre, their affiliates, their respective boards of directors and stockholders, the Dealer Manager, the Tender Agent or Computershare Trust Company, N.A., as trustee and collateral agent for the Securities, are making any recommendation as to whether Holders should tender any Securities in response to the Tender Offers. Holders must make their own decision as to whether to tender any of their Securities, and, if so, the principal amount of Securities to tender.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any of the Securities, and the Tender Offers do not constitute offers to buy or the solicitation of offers to sell Securities in any jurisdiction or in any circumstances in which such offers are unlawful. The full details of the Tender Offers, including complete instructions on how to tender Securities, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase because it will contain important information.

Forward-Looking Statements

Certain statements herein are forward-looking statements about trends, future events, uncertainties and our plans and expectations of what may happen in the future. Any statements that are not historical or current facts are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "expect," "guidance," "outlook," "trend," "pro forma," "on course," "on track," "target," "potential," "benefit," "goal," "believe," "plan," "confident," "anticipate," "indicate," "trend," "position," "optimistic," "will," "forecast," "continue," "strategy," "estimate," "project," "may," "should," "would," "intend," or the negative of these terms, where applicable, or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. More information about potential risks and uncertainties that could materially affect our business and results of operations is included in the "Risk Factors" and "Forward-Looking Statements" sections in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 18, 2026 and in our other filings with the SEC, as well as other risks and uncertainties specified in the "Certain Significant Considerations" section of the Offer to Purchase. We cannot guarantee future events, including financing of the Tender Offers and successful completion of the Tender Offers, outlook, guidance, results, actions, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date they are made.

About Sabre

Powering the agentic revolution in travel. Sabre is an AI-native technology leader, backed by one of the world's largest travel data clouds. With AI at its core and operating at unparalleled scale, Sabre transforms insights into innovation, empowering airlines, hoteliers, agencies and other partners to retail, distribute and fulfill travel worldwide. Sabre is built on an open, modular, cloud-native architecture and serves as the backbone for both established leaders and bold, new disruptors, guiding them to the next age of travel retailing through intelligent, connected, and personalized experiences.

SABR-F

Contacts:

SOURCE Sabre Corporation

Share this article

MetaOptics Ltd establishes American Depositary Receipt ("ADR") Programme on OTCQX in the U.S., with J.P. Morgan as the Depositary Bank

SINGAPORE, Sept. 24, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group"), a leading-edge semiconductor optics company, today announced the establishment of its sponsored Level 1 ADR programme in the U.S. (the "ADR Programme"), under which American Depositary Shares ("ADSs") will trade on OTCQX.

The Company has appointed J.P. Morgan as the depositary bank for the ADR Programme. The ADR Programme does not involve any capital raising or the issuance of new shares by the Company. The Company's ordinary shares will continue to trade on the Catalist board of the SGX Stock Exchange and the ADR Programme is not expected to have any material impact to existing shareholders of the Company.

Trading on OTCQX, the highest-level market of Over The Counter ("OTC") Markets

OTCQX is the highest-level market operated by OTC Markets Group, which operates regulated markets for more than 12,000 U.S. and international securities. OTCQX is designed for established, investor-focused U.S. and international companies and requires companies to meet prescribed financial standards, follow best-practice corporate governance and demonstrate compliance with applicable securities laws.

Joining a growing group of Singapore-listed companies accessible to U.S. investors

The Company's ADR Programme on OTCQX places it within a broader ecosystem of Singapore-listed companies whose shares are also accessible to U.S. investors. These include prominent names such as Singapore Exchange Ltd. (SGX Group), which also trades on OTCQX.

Expanding the Company's global shareholder base

Following the Company's successful listing on the Catalist of the SGX-ST in September 2025, its participation in CES 2025 and CES 2026, as well as recent product and technology roadshows in the U.S., the Group's engagement and collaboration with U.S. industry partners, customers and institutional investors, has validated its growth and expansion plans in the U.S. including the establishment of the Group's maiden front-end semiconductor fabrication line with 12-inch DUV immersion photolithography equipment in the U.S., for the mass production of metalenses and modules. With the Group's continued and ongoing expansion in the U.S., the ADR Programme is intended to broaden the Company's international investor reach and provide U.S.-based investors with a more convenient channel to access and trade the Company's securities, and to provide a platform for U.S. investors to directly participate in the Company's growth story. The Company believes that greater access to U.S. investors will be particularly relevant as it progresses its next phase of commercialisation and development.

In addition, the ADR Programme will provide Singapore-based investors around-the-clock access to trade in the Company's shares, via OTCQX and its local listing on the SGX Stock Exchange. The ADS conversion can be effected through J.P. Morgan as the Company's depositary bank, and trading of the ADSs through U.S. brokers and trading platforms. Singapore-based investors who wish to trade in the ADSs through Singapore-based brokers and trading platforms, are able to do so via such brokers and trading platforms, and can reach out to their respective trading representatives for further details.

Investors who wish to find out more about the conversion and/or ADSs issuance on OTCQX may refer to https://adr.com/ for the related forms and instructions. J.P. Morgan's Settlement and Operations team will also be available to assist investors and/or their brokers, and can be contacted at [email protected].

Supporting the Group's commercialisation and collaboration in the U.S.

The ADR Programme complements the Company's deployment of its key direct laser writers ("DLW") at the nano@stanford facility and the University of Arizona's Centre of Semiconductor Manufacturing, to further expand the Group's engagement within the U.S. technology and research ecosystems, and support the Group's U.S. expansion strategy, prospective U.S. customer engagement, and commercialisation roadmap, including the establishment of the Group's maiden front-end semiconductor fabrication line with 12-inch DUV immersion photolithography equipment in the U.S., for the mass production of metalenses and modules.

Mr Thng Chong Kim, Executive Chairman said "The ADR Programme on OTCQX provides us an additional platform to introduce and increase awareness of our technology and solutions, and provides U.S. investors with a dedicated and accessible trading channel for our shares, which will help us broaden our shareholder base, enhance the potential for liquidity and international visibility, and bring our growth story to a wider investment community. This is particularly relevant, as we progress on our next phase of commercialisation and expansion in the U.S.."

About MetaOptics Ltd

MetaOptics Ltd (Catalist: 9MT) is a leading-edge semiconductor optics company pioneering glass-based metalens solutions enhanced by AI-driven image processing. Using advanced optical design and a scalable 12-inch DUV lithography process, it powers next-generation applications in CPO, mobile, AR VR, automotive and other emerging markets. Headquartered in Singapore, MetaOptics aims to deliver high-performance optics with the reliability and scalability demanded by today's most innovative technology brands. Find out more at www.metaoptics.sg.

Forward-Looking Statements

This press release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the Company's growth strategies, its future business development, results of operations and financial condition, its research and development efforts, its ability to attract and retain customers, and its ability to establish and maintain relationships with suppliers and business partners; and assumptions underlying or related to any of the foregoing. All information provided in this press release is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Singapore (Headquarters)

MetaOptics Technologies Pte Ltd, 81 Ayer Rajah Crescent, #01-45, Singapore 139967

United States

MetaOptics Inc. (USA), 1 Ferry Building, Suite 201, San Francisco, CA 94111

SOURCE METAOPTICS LTD

Share this article

Four Years in Development, Engineered to Disrupt the Kitchen—Again

NEW YORK, Sept. 16, 2026 /PRNewswire/ -- HexClad, the revolutionary kitchen brand that pioneered the hybrid cookware category, today announced HexClad Hybrid Bakeware, taking its category-defining approach from the stovetop to the oven.

Four years in the making, the 6-piece collection was meticulously engineered to challenge the limitations of traditional nonstick bakeware. HexClad reengineered its signature hybrid technology for baking, developing a new formulation of PFAS-free TerraBond™ ceramic nonstick that delivers effortless release and withstands oven temperatures up to 900°F. Each piece is metal-utensil and dishwasher safe, engineered to resist warping, distribute heat evenly and deliver consistent results bake after bake—all backed by HexClad's industry-leading lifetime warranty.

"Bakeware has been one of the most requested categories from our customers, but solving it the HexClad way was much more complicated than simply taking our cookware and putting it in the oven," said Daniel Winer, CEO and Co-Founder of HexClad. "We wanted the easy release people love about nonstick without the compromises they've come to accept. It took four years because we kept pushing until we had the right combination of nonstick performance, durability and consistency. If we're going to enter a category, we want to raise the standard for it."

HexClad Hybrid Bakeware Collection includes:

- 9" x 13" Rectangular Cake Pan

- 9" Round Cake Pans (2)

- 8" x 8" Square Cake Pan

- 10" x 15" Medium Baking Sheet

- 9.5" x 14.5" Stainless-Steel Cooling Rack

Throughout development, the collection was rigorously tested by HexClad's product and engineering teams, as well as members of its Global Culinary Council, including Gordon Ramsay, Massimo Bottura, Dominique Crenn, Nancy Silverton, Clare Smyth and Paul Ainsworth. Their feedback helped refine the collection under real-world cooking conditions and ensure it could deliver the level of performance demanded by professional chefs while remaining intuitive for home cooks.

The launch marks an important global expansion beyond the stovetop for HexClad, bringing the brand's approach to hybrid innovation and professional-grade performance for the home cook to one of the most-used, and historically under-innovated, areas of the kitchen.

HexClad Hybrid Bakeware is available for pre-sale beginning today, with individual pieces and collection sets ranging from $179 to $399. Orders are expected to begin shipping by October 5.

For more information visit www.hexclad.com

About HexClad

HexClad is a global premium kitchenware brand based in Los Angeles, known for its patented hybrid technology that combines stainless steel with nonstick for unmatched performance, durability, and ease-of-use. Since its founding in 2016, HexClad has redefined modern cooking tools with a full line of high-performance products, including cookware, cutlery, cutting boards, aprons, and kitchen accessories. Sold through direct-to-consumer channels and strategic retail partners, HexClad has built a passionate global following by empowering cooks of all levels with products that break rules and challenge convention. The brand was named to the Inc. 5000 list of the fastest-growing private companies in America 2023-2025. Learn more at www.hexclad.com.

Update: Collection details have been updated.

SOURCE HexClad

Share this article

Expanded committed capacity enhances financial flexibility

RALEIGH, N.C., Sep 24, 2026 /PRNewswire/ -- Cardinal Infrastructure Group Inc. (Nasdaq: CDNL) ("Cardinal" or the "Company") today announced that its subsidiary, Cardinal Civil Contracting, LLC, has entered into a second amendment to its senior secured credit agreement. The amendment adds a new delayed draw term loan facility of up to $250 million and raises the revolving credit facility from $75 million to $100 million.

With the amendment, Cardinal's total credit facility commitments are $550 million, comprised of the $100 million revolver, the existing Term Loan A (originally $200 million) and the new $250 million delayed draw term loan.

Key terms of the amended facility include:

- $250 million delayed draw term loan. The Company can draw in as many as five separate advances over 18 months through March 2028. The Company intends to use the proceeds to finance permitted acquisitions and related fees and expenses. The delayed draw term loan facility was undrawn at the completion of the syndication.

- $100 million revolving credit facility, increased from $75 million. It includes a $10 million letter of credit sub-facility and a $10 million swingline sub-facility, which is available for working capital and general corporate purposes.

- Maturity for the revolver, Term Loan A and delayed draw term loan is September 10, 2031.

- The new commitments are additive to the facility's existing incremental capacity.

"This financing gives us the flexibility to expand our capabilities and geographic reach through disciplined acquisitions, while continuing to serve our customers by leveraging our differentiated in-house teams and equipment," said Jeremy Spivey, Chief Executive Officer of Cardinal.

"This amendment gives us the necessary capital to selectively pursue acquisitions while maintaining a disciplined approach to the balance sheet," said Mike Rowe, Chief Financial Officer of Cardinal. "We appreciate the continued support of our lending partners."

More details on the amendment are in the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on September 11, 2026.

About Cardinal

Cardinal Infrastructure Group Inc. (NASDAQ: CDNL) is one of the Southeast's fastest-growing, full-service infrastructure service providers. The Company delivers integrated civil and site development solutions across high growth markets through a self-performing model supported by skilled labor, specialized fleets and market leading subsidiaries. This model enables efficient, turnkey project execution at scale while maintaining focus on building long-term client relationships. Cardinal's strategy is grounded in operational discipline, market expansion and a commitment to integrity from the ground up.

Important Information for Investors and Stockholders

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning, among other things, Cardinal Infrastructure Group, Inc.'s ("Cardinal") amended credit facility, the anticipated use of borrowings thereunder, and Cardinal's acquisition strategy. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include the words "may," "could," "plan," "project," "budget," "predict," "pursue," "target," "seek," "objective," "believe," "expect," "anticipate," "intend," "estimate," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These statements involve risks and uncertainties, and Cardinal's actual results could differ materially from the results expressed or implied by such forward-looking statements. The potential risks, uncertainties and other factors that could cause actual results to differ from those expressed by the forward-looking statements in this press release include, but are not limited to, Cardinal's ability to identify, complete and finance suitable acquisitions; the risk that any acquisition will not deliver its anticipated benefits to the extent or when expected; the risk that integrating acquired businesses will be materially delayed or will be more costly or difficult than expected; Cardinal's ability to satisfy the conditions to borrowing under, and comply with the covenants of, its credit agreement; the effect of increased indebtedness and changes in interest rates on Cardinal's financial condition; difficulty in sustaining rapid revenue growth, which may place significant demands on Cardinal's administrative, operational and financial resources; fluctuations in Cardinal's revenue; and the concentration of Cardinal's business in the Southeastern United States. Cardinal has based these forward-looking statements largely on its current expectations and projections regarding future events and trends that it believes may affect its business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section entitled "Risk Factors" in Cardinal's Registration Statement on Form S-1 (333-292034) (the "Registration Statement"), and elsewhere in the Registration Statement. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Cardinal cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. Although forward-looking statements reflect the good faith beliefs of Cardinal's management at the time they are made, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from anticipated future results, performance or achievements expressed or implied by such forward-looking statements. Cardinal undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. These cautionary statements qualify all forward-looking statements attributable to Cardinal or persons acting on its behalf.

SOURCE Cardinal Infrastructure Group Inc.

Share this article

PUNE, India, Sept. 24, 2026 /PRNewswire/ -- Global Autoimmune Treatment Market was valued at USD 176.6 Billion in 2025 and is projected to expand at a 6.9% CAGR from 2026 to 2034, reaching USD 321.95 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Autoimmune Treatment Market

The Global Autoimmune Treatment Market Report 2025 provides a comprehensive analysis of market trends, autoimmune disease prevalence, patient population, treatment procedures, therapeutic approaches, drug development pipeline, clinical research, technological advancements, regulatory developments, competitive landscape, treatment adoption, and market forecasts through 2034. The market covers rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, and other autoimmune disorders across anti-inflammatory drugs, anti-hyperglycaemic drugs, NSAIDs, interferons, immunosuppressants, biologics, and other therapeutic approaches.

The rising prevalence of autoimmune diseases, growing geriatric population, increasing disease awareness, demand for early diagnosis, and expanding access to advanced healthcare are supporting the growth of the global autoimmune treatment market. Increasing adoption of biologics, immunosuppressive therapies, corticosteroids, monoclonal antibodies, targeted therapies, anti-inflammatory drugs, disease-modifying therapies, and personalized treatment is transforming autoimmune disease management. Growing investments in pharmaceutical research, clinical trials, biotechnology, drug discovery, immunology, and novel therapeutic development are further expanding treatment opportunities for patients with chronic, progressive, inflammatory, and systemic autoimmune disorders.

Advancements in biologic therapies, targeted immunotherapy, monoclonal antibodies, biosimilars, cytokine inhibitors, JAK inhibitors, precision medicine, molecular diagnostics, biomarker testing, digital health technologies, and personalized autoimmune treatment are reshaping the autoimmune treatment landscape. Increasing research into rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, and other autoimmune disorders is creating new opportunities for pharmaceutical and biotechnology companies. Product launches, FDA approvals, clinical trial advancements, strategic collaborations, licensing agreements, acquisitions, pipeline expansion, and investments in next-generation immunotherapies and targeted autoimmune therapies are expected to accelerate innovation and strengthen the global autoimmune treatment market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/198275/

Global Autoimmune Treatment Market gains momentum as rising prevalence of autoimmune diseases, growing demand for advanced treatment, increasing adoption of biologics, immunosuppressants, anti-inflammatory drugs and targeted therapies, advances in monoclonal antibodies, biosimilars and immunotherapy, and expanding precision medicine, biomarker-driven treatment and personalized healthcare approaches accelerate therapeutic innovation: Maximize Market Research unveils key market insights.

Global Autoimmune Treatment Market Size & Forecast

Global Autoimmune Treatment Market Trends & Insights

- North America leads the Global Autoimmune Treatment Market, supported by advanced healthcare infrastructure, high prevalence of autoimmune diseases, strong pharmaceutical R&D, established specialist care, and increasing adoption of advanced autoimmune therapies.

- Asia-Pacific is a high-growth region, driven by rising autoimmune disease awareness, improving healthcare infrastructure, growing healthcare expenditure, expanding access to diagnosis and treatment, and increasing demand for biologics and targeted therapies.

- Biologics and targeted therapies are gaining adoption, with growing use of monoclonal antibodies, immunosuppressants, anti-inflammatory drugs, interferons, disease-modifying therapies, and other advanced treatment approaches for autoimmune disorders.

- Personalized and precision treatment approaches are expanding, supported by advances in biomarker testing, molecular diagnostics, immunology research, targeted immunotherapy, and patient-specific treatment strategies for chronic and complex autoimmune diseases.

- Pharmaceutical R&D and novel drug development are driving treatment innovation, with increasing clinical trials, product launches, biosimilar development, strategic collaborations, and investments in next-generation therapies for rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, and other autoimmune disorders.

Rising Prevalence of Autoimmune Diseases Drives Market Growth

The increasing prevalence of autoimmune diseases, growing geriatric population, rising disease awareness, and greater emphasis on early diagnosis are driving demand for effective autoimmune treatments. The increasing patient burden of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, and other autoimmune disorders is supporting the adoption of anti-inflammatory drugs, anti-hyperglycaemic drugs, NSAIDs, interferons, immunosuppressants, biologics, and targeted therapies.

High Treatment Costs and Long-Term Therapy Restrain Market Growth

The high cost of biologics, targeted therapies, immunotherapies, advanced diagnostic procedures, and prolonged disease management can limit patient access to autoimmune treatments. Expensive monoclonal antibodies, specialty medicines, immunosuppressive therapies, and personalized treatment approaches create affordability and reimbursement challenges, particularly across developing and cost-sensitive markets. Long-term treatment requirements and concerns regarding adverse effects associated with certain immunosuppressive therapies can further affect treatment adoption.

Advancements in Biologics and Targeted Therapies Create Opportunities

Rapid development of biologics, monoclonal antibodies, biosimilars, targeted immunotherapies, cytokine inhibitors, JAK inhibitors, and disease-modifying therapies is creating new opportunities in the autoimmune treatment market. Growing investment in pharmaceutical R&D, clinical trials, novel drug discovery, precision medicine, biomarker testing, molecular diagnostics, and personalized treatment is expanding therapeutic options for patients with chronic and complex autoimmune disorders. Increasing development of next-generation therapies is also creating opportunities for pharmaceutical and biotechnology companies.

Limited Healthcare Infrastructure and Specialist Access Create Challenges

Limited access to advanced diagnostic facilities, specialist healthcare professionals, autoimmune disease screening, and modern treatment options remains a challenge across several developing regions. Differences in healthcare infrastructure, treatment accessibility, reimbursement coverage, regulatory requirements, availability of biologics, and access to specialized rheumatology, immunology, endocrinology, gastroenterology, and neurology services can restrict the adoption of advanced autoimmune therapies. Disease heterogeneity, delayed diagnosis, and variations in patient response also increase the complexity of treatment selection and long-term disease management.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/198275/

Global Autoimmune Treatment Market Segmentation

The Global Autoimmune Treatment Market is segmented by Product, Drug Class, Treatment, Indication, Distribution Channel, and Region. Rising prevalence of autoimmune diseases, growing demand for effective disease management, increasing adoption of biologics and targeted therapies, advances in immunotherapy and personalized treatment, and expanding pharmaceutical R&D are supporting market development across these segments.

North America Leads the Autoimmune Treatment Market While Europe and Asia Pacific Present Significant Growth Opportunities

North America held the largest share of the Global Autoimmune Treatment Market in 2025, supported by the high prevalence of autoimmune diseases, advanced healthcare infrastructure, strong pharmaceutical R&D, established specialist care, and high healthcare expenditure. The United States represents a major market due to the presence of leading pharmaceutical and biotechnology companies, advanced diagnostic facilities, and growing adoption of biologics, immunosuppressants, monoclonal antibodies, targeted therapies, and personalized treatment. Canada and Mexico are also contributing through improving healthcare infrastructure, increasing disease awareness, and expanding access to advanced autoimmune therapies.

Europe represents an important market, supported by established healthcare systems, strong pharmaceutical and biotechnology industries, and increasing investments in autoimmune disease research. Germany, the United Kingdom, France, Italy, Spain, Sweden, Switzerland, and other European countries are witnessing growing adoption of biologics, anti-inflammatory drugs, immunosuppressants, targeted therapies, interferons, and disease-modifying treatments. Increasing clinical research, pharmaceutical R&D, biomarker testing, and regulatory support for innovative therapies are further supporting regional development.

Asia Pacific is expected to witness strong growth as healthcare infrastructure, disease awareness, diagnostic capabilities, and access to advanced treatment improve. China, Japan, India, South Korea, Australia, and other regional markets are contributing to market development.

PUNE, India, Sept. 24, 2026 /PRNewswire/ -- The Global Nanomedicine Market was valued at USD 207.91 Billion in 2025 and is projected to expand at a 12.1% CAGR from 2025 to 2034, reaching USD 581.2 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Nanomedicine Market

The Global Nanomedicine Market Report 2025 provides a comprehensive analysis of market trends, nanotechnology adoption, nanomedicine applications, clinical developments, therapeutic innovations, diagnostic technologies, drug delivery systems, regulatory developments, competitive landscape, technology advancements, and market forecasts through 2034. The market covers nanomedicine applications across diagnostics and imaging, treatment, drug delivery, vaccines, regenerative medicine, implants, and other healthcare applications, supporting the development of advanced solutions for cancer, infectious diseases, cardiovascular disorders, neurological conditions, ophthalmic diseases, and other chronic and complex conditions.

The rising prevalence of chronic and complex diseases, growing demand for targeted therapies, increasing adoption of personalized medicine, and advances in nanoscale technologies are supporting the growth of the global nanomedicine market. Increasing use of nanoparticle-based drug delivery, nanodiagnostics, nano-enabled vaccines, nanostructured implants, and precision therapeutic platforms is transforming disease diagnosis and treatment. Growing investments in nanotechnology research, pharmaceutical R&D, biotechnology, clinical development, and advanced healthcare technologies are further expanding opportunities for nanomedicine-based products and therapies.

Advancements in nanocarriers, lipid nanoparticles, nanoparticle-based drug delivery, nano-enabled diagnostics, nanobiosensors, nanostructured implants, regenerative medicine, targeted cancer therapies, and precision medicine are reshaping the nanomedicine landscape. Increasing research into oncology, infectious diseases, cardiology, neurology, ophthalmology, orthopedics, and immunology is creating new opportunities for pharmaceutical, biotechnology, medical device, and nanotechnology companies. Product launches, clinical developments, strategic collaborations, technology investments, regulatory advancements, and expansion of nanotechnology applications are expected to accelerate innovation and strengthen the global nanomedicine market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/39223/

Global Nanomedicine Market gains momentum as rising chronic disease prevalence, growing demand for targeted drug delivery, increasing adoption of nanotechnology-based diagnostics and therapeutics, advances in nanoparticle platforms and precision medicine, and expanding applications across oncology and other therapeutic areas accelerate healthcare innovation: Maximize Market Research unveils key market insights.

Global Nanomedicine Market Size & Forecast

Global Nanomedicine Market Trends & Insights

- North America leads the Global Nanomedicine Market, supported by advanced healthcare infrastructure, strong pharmaceutical and biotechnology R&D, significant investment in nanotechnology, and widespread adoption of advanced diagnostic and therapeutic technologies.

- Asia-Pacific represents a high-growth region, driven by expanding healthcare infrastructure, increasing investments in nanotechnology research, rising disease burden, growing pharmaceutical R&D, and increasing adoption of nanomedicine applications across China, Japan, India, and other emerging markets.

- Nanotechnology-based drug delivery is gaining adoption, supported by the growing use of nanoparticles, lipid nanoparticles, liposomes, and other nanocarriers for targeted drug delivery, improved therapeutic efficacy, enhanced bioavailability, and reduced treatment-related side effects.

- Nanomedicine applications in oncology and diagnostics are expanding, with increasing development of nano-enabled cancer therapies, molecular diagnostics, imaging technologies, biosensors, and precision treatment platforms for early disease detection and targeted intervention.

- Precision medicine is driving nanomedicine innovation, with growing research into personalized therapies, advanced nanomaterials, targeted delivery systems, regenerative medicine, nano-enabled vaccines, and next-generation treatment platforms across oncology, infectious diseases, cardiology, neurology, ophthalmology, and orthopedics.

Increasing Adoption of Nanotechnology-Based Drug Delivery Drives Market Growth

The growing adoption of nanotechnology in drug delivery is driving demand for more precise and effective therapeutic solutions. Nanoparticles, lipid nanoparticles, liposomes, and other nanocarriers can support targeted drug delivery, improve bioavailability, enhance therapeutic efficacy, and reduce exposure to healthy tissues. Increasing applications across oncology, infectious diseases, cardiovascular disorders, neurological conditions, and ophthalmology are strengthening the role of nanomedicine in advanced healthcare.

High Development and Manufacturing Costs Restrain Market Growth

The high cost associated with nanomedicine research, clinical development, specialized manufacturing, quality control, and regulatory compliance can limit market expansion. Complex production processes and the need for advanced expertise and infrastructure can increase development costs compared with conventional pharmaceutical formulations, creating affordability and commercialization challenges, particularly in cost-sensitive healthcare markets.

Advancements in Precision Medicine and Nano-Enabled Therapeutics Create Opportunities

Rapid developments in nanoparticle-based drug delivery, lipid nanoparticles, nanodiagnostics, nano-enabled vaccines, regenerative medicine, and targeted therapies are creating new opportunities. Growing research in personalized medicine, cancer treatment, molecular diagnostics, and advanced therapeutic platforms is further expanding the application scope of nanomedicine and encouraging pharmaceutical and biotechnology companies to invest in next-generation solutions.

Regulatory Complexity and Limited Specialized Infrastructure Create Challenges

The absence of standardized regulatory approaches specifically tailored to nanomedicine, combined with complex product classification, safety assessment, characterization, and approval requirements, remains a challenge. Limited access to specialized nanotechnology manufacturing facilities, skilled professionals, advanced testing capabilities, and supporting healthcare infrastructure in developing markets can also restrict the adoption and commercialization of innovative nanomedicine products.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/39223/

Global Nanomedicine Market Segmentation

The Global Nanomedicine Market is segmented by Product Type, Application, Indication, and Region. Rising demand for targeted drug delivery, increasing adoption of nanotechnology-based diagnostics and therapeutics, growing prevalence of chronic and complex diseases, advances in personalized medicine, and expanding research and development in nanotechnology are supporting market development across these segments.

North America Leads the Nanomedicine Market with Strong Healthcare Infrastructure and R&D Capabilities

North America held the largest share of the Global Nanomedicine Market in 2025, supported by advanced healthcare infrastructure, strong pharmaceutical and biotechnology research, high healthcare expenditure, and significant investment in nanotechnology. The United States represents a major market due to its established research ecosystem, leading pharmaceutical and biotechnology companies, advanced clinical infrastructure, and increasing adoption of nanotechnology-based drug delivery, diagnostics, targeted therapies, and precision medicine. Canada and Mexico are also contributing through expanding healthcare capabilities, research initiatives, and growing adoption of advanced medical technologies.

Europe represents an important market, supported by established healthcare systems, strong pharmaceutical and biotechnology industries, and increasing investments in nanotechnology and biomedical research. Germany, the United Kingdom, France, Italy, Spain, Sweden, Austria, and other European countries are witnessing increasing adoption of nanomedicine across drug delivery, diagnostics and imaging, vaccines, regenerative medicine, and targeted therapies. Growing clinical research, technological development, and regulatory initiatives are further supporting regional market development.

Asia Pacific is expected to witness strong growth as healthcare infrastructure, pharmaceutical R&D, and nanotechnology capabilities continue to expand. China, Japan, India, South Korea, Australia, and other regional markets are contributing to market development through increasing investments in nanotechnology research, clinical applications, drug delivery systems, nano-enabled diagnostics, vaccines, and precision medicine. China is emerging as a major nanotechnology and nanomedicine hub, supported by research capabilities, government-backed initiatives, and expanding pharmaceutical and biotechnology activity.

Middle East & Africa is gradually developing as healthcare infrastructure, specialized medical services, and access to advanced technologies improve. GCC countries, South Africa, Egypt, Nigeria, and other markets are investing in modern healthcare facilities, advanced diagnostics, pharmaceutical development, and specialized treatment capabilities.

Lovery Real Estate Launches Homeowner Program for Renovation Guidance

Extending guidance beyond the final sale helps Lovery Real Estate build lasting relationships.

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Lovery Real Estate announced the launch of its Lovery Homeowner Program, which formalizes several core company services. Until now, clients have received renovation guidance, design direction, and vetted contractor contacts through informal processes. The Homeowner Program makes that a defined part of what the company does, regardless of the agent.

Origins of Lovery Real Estate

Before he founded Lovery Real Estate in 2025, Ryan Fisher played professional baseball. Although he doesn't talk much about the game, it taught him the discipline he needed to succeed in a market as competitive as real estate. Now, he works with buyers, sellers, and investors across San Diego County, building relationships that go beyond handing over keys.

Where the traditional residential brokerage model would end at the transaction, Fisher recognizes that as the moment the client has the most questions. Perhaps the house needs work, but they don't know what's worth doing, who to call, or what's a reasonable cost. Few brokerages are structured to help; that's where the Lovery Homeowner Program makes a difference.

Helping Clients That Aren't Prepared

Often, Lovery Real Estate works with people who weren't prepared to sell their home. Whether due to probate, divorce, pre-foreclosure, or other circumstances, complexity can arise when clarity is essential. While an agent might be prepared to help with the sale itself, they often neglect the aftermath. In these scenarios, the Lovery Homeowner Program bridges the gap.

"So the help is not encouragement," Fisher explained. "It is accurate information early enough to be useful, honest math on each path, and being the person who handles the parts they should not have to learn."

Instead of leaving clients holding the keys and walking away with a completed transaction, the Lovery Homeowner Program ensures the relationship continues as long as the client needs it. When the house needs work and the client isn't sure where to go next, they can find answers from a source they can rely on.

Looking to the Buy Side

Beyond home sales, Lovery Real Estate also helps clients buy homes. Even in these circumstances, the firm takes a relationship-based approach. Clients receive renovation guidance, project ideas, and contractor contacts to ensure they aren't starting from scratch. This support, on both the buying and selling sides of the market, has helped Lovery Real Estate grow.

Beyond the Completed Sale

Through its Lovery Homeowner Program, Lovery Real Estate extends its long-term support. In doing so, the firm supports its clients beyond the completed sale. Although there's no commission attached, Lovery Real Estate understands that the client relationship matters most.

About Lovery Real Estate

Lovery Real Estate is a boutique San Diego team led by Ryan Fisher. The firm built its model on a construction-family lens, prioritizing how customers want to be treated. With each property, Lovery Real Estate aims to do things right, preparing and positioning the home to deliver results.

Media Contact:

Company Name: Lovery Real Estate

Contact Name: Ryan Fisher

City/State: San Diego, CA

Email: [email protected]

Phone: (619) 651-9869

SOURCE Lovery Real Estate

Share this article